FSR's Blog — Page 45 of 115 — Foundation for Sarcoidosis Research

Dr. Nicholas Arger Receives ATS Foundation Research Program/Foundation for Sarcoidosis Partner Grant

Jan 9, 2020

(Jan. 9, 2020) — The ATS Foundation Research Program/Foundation for Sarcoidosis has awarded Nicholas Arger, MD, of the University of California, San Francisco a $80,000 Foundation Partner grant. The ATS Foundation Partner Grant provides crucial support to...

Topics: Other

aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

Jan 9, 2020

FSR has partnered with aTyr Pharma, Inc. to help inform patients about an ongoing clinical trial for ATYR1923, a potential new treatment for pulmonary sarcoidosis (ATYR1923-C-002, NCT03824392.) aTyr recently issued a press release, republished with permission below,...

Topics: Research

Clinical Trial: Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Jan 8, 2020

New clinical trial opportunity in New Haven, CT!

Topics: Research

Sarcoidosis and Quality of Life: A Dissertation

Jan 6, 2020

Since sarcoidosis is a rare disease, there is a lot we don’t know about it. Scientists are working diligently to figure out the cause of sarcoidosis as well as find drugs that can be used to treat it. We already know how important these clinical trials are for...

Topics: Living with Sarcoidosis

Blog

Dr. Nicholas Arger Receives ATS Foundation Research Program/Foundation for Sarcoidosis Partner Grant

aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

Clinical Trial: Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Sarcoidosis and Quality of Life: A Dissertation

Categories

Recent Posts